Get the Stockscreener App
2.18
3.54%
-0.08
After Hours:
2.18
Achieve Life Sciences Inc stock is traded at $2.18, with a volume of 817.66K.
It is down -3.54% in the last 24 hours and down -48.22% over the past month.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
See More
Previous Close:
$2.26
Open:
$2.29
24h Volume:
817.66K
Relative Volume:
3.45
Market Cap:
$127.99M
Revenue:
-
Net Income/Loss:
$-32.94M
P/E Ratio:
-1.964
EPS:
-1.11
Net Cash Flow:
$-24.95M
1W Performance:
-37.89%
1M Performance:
-48.22%
6M Performance:
-41.08%
1Y Performance:
-51.66%
1-Day Range:
$2.1506
$2.29
1-Week Range:
$2.00
$2.65
52-Week Range:
$1.84
$5.31
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
2.18 | 127.99M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
Achieve Life Sciences Inc Stock (ACHV) Latest News
Bank of America Corp DE Purchases 9,760 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Institutional investors may adopt severe steps after Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) latest 15% drop adds to a year losses - simplywall.st
Owning 46% shares,institutional owners seem interested in Achieve Life Sciences, Inc. (NASDAQ:ACHV), - Yahoo Finance
Squarepoint Ops LLC Buys Shares of 17,519 Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
achieve life sciences holds annual meeting with key votes By Investing.com - Investing.com India
Achieve Life Sciences Elects Board at Annual Meeting - TipRanks
achieve life sciences holds annual meeting with key votes - Investing.com
Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk (ACHV) - Seeking Alpha
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Late-Stage Smoking Cessation Drug Developer Achieve Life Sciences Sets Key Jefferies Conference Presentation - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Purchased by Northern Trust Corp - Defense World
Shay Capital LLC Sells 425,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
ACHV: New Insights from ORCA-3 Study to Be Shared at 2025 Conference | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present Phase 3 Study Findings on Cytisinicline for Smoking Cessation at 2025 ATS Conference - Nasdaq
Achieve Life Sciences to Present New Data at the 2025 ATS - GlobeNewswire
New Clinical Data Shows Cytisinicline Cuts Nicotine Cravings in Phase 3 Trial | ACHV Stock News - Stock Titan
Brokers Offer Predictions for ACHV Q3 Earnings - Defense World
Tower Research Capital LLC TRC Acquires 4,905 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
What is Zacks Small Cap’s Estimate for ACHV Q2 Earnings? - Defense World
Achieve Life Sciences targets NDA submission for cytisinicline in June 2025 as open label study hits key milestones - MSN
Raymond James Financial Inc. Purchases New Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2025 Earnings Call Transcript - Insider Monkey
ACHV: Kicking Butts to Achieve June NDA Filing - Yahoo Finance
Achieve Life Sciences Inc (ACHV) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Achieve Life Sciences Inc (ACHV) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Achieve Life Sciences Q1 2025 targets nicotine dependence market - Investing.com Nigeria
Earnings call transcript: Achieve Life Sciences Q1 2025 targets nicotine dependence market By Investing.com - Investing.com South Africa
Transcript : Achieve Life Sciences, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
ACHV Prepares for FDA Submission of New Smoking Cessation Drug | - GuruFocus
Achieve Life Sciences Inc Reports Q1 2025 EPS of -$0.37, Aligns with Estimates; Revenue Remains at $0 Million - GuruFocus
ACHIEVE LIFE SCIENCES Earnings Results: $ACHV Reports Quarterly Earnings - Nasdaq
Achieve Life Sciences Reports First Quarter 2025 Financial Resul - GuruFocus
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program - The Manila Times
Achieve Life Sciences Inc. Q1 Loss Increases In Line With Estimates - Nasdaq
ACHIEVE LIFE SCIENCES, INC. SEC 10-Q Report - TradingView
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Bought by Barclays PLC - Defense World
Raymond James Financial Inc. Takes $554,000 Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Wells Fargo & Company MN Boosts Holdings in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Renaissance Technologies LLC Increases Stock Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Thursday - MarketBeat
Will Cytisinicline Achieve The Long-Awaited Breakthrough In Nicotine Addiction Treatment? - RTTNews
Achieve Life Sciences to Announce First Quarter 2025 Financial R - GuruFocus
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025 | ACHV Stock News - GuruFocus
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025 - The Manila Times
Achieve Life Sciences to Announce First Quarter 2025 - GlobeNewswire
Achieve Life Sciences to Report Q1 Earnings: Latest Updates on Smoking Cessation Drug Development - Stock Titan
Achieve Life Sciences Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stewart Richard Alistair | Chieve Executive Officer |
Mar 17 '25 |
Buy |
2.86 |
10,000 |
28,598 |
60,876 |
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):